Cheson Bruce D
Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA.
Semin Oncol. 2007 Dec;34(6 Suppl 5):S3-7. doi: 10.1053/j.seminoncol.2007.11.001.
Peripheral T-cell non-Hodgkin's lymphomas are a diverse group of disorders, most of which carry a poor prognosis. Relapse is common following the administration of most currently available agents, and there are few effective options for salvage therapy. This article discusses a number of novel emerging therapies for the treatment of patients with T-cell non-Hodgkin's lymphomas, including the antimetabolite nelarabine, the purine nucleoside phosphorylase inhibitor forodesine, the pyrimidine analogue gemcitabine, and the fusion protein denileukin diftitox. Other therapies discussed for the treatment of patients with T-cell non-Hodgkin's lymphomas include bendamustine, gallium nitrate, and bortezomib, as well as the mammalian target of rapamycin inhibitors, small molecules that target the apoptotic pathways, immunomodulatory agents, and monoclonal antibodies.
外周T细胞非霍奇金淋巴瘤是一组多样的疾病，其中大多数预后不良。使用目前大多数可用药物治疗后复发很常见，挽救治疗的有效选择很少。本文讨论了一些用于治疗T细胞非霍奇金淋巴瘤患者的新兴疗法，包括抗代谢药奈拉滨、嘌呤核苷磷酸化酶抑制剂福达华、嘧啶类似物吉西他滨以及融合蛋白地尼白介素-毒素连接物。讨论的用于治疗T细胞非霍奇金淋巴瘤患者的其他疗法包括苯达莫司汀、硝酸镓和硼替佐米，以及雷帕霉素靶蛋白抑制剂、靶向凋亡途径的小分子、免疫调节剂和单克隆抗体。
